Ultrasighttm To Expand Access To Echocardiographic Monitoring For Obstructive Hypertrophic Cardiomyopathy Patients

(MENAFN- EIN Presswire)

In a new study, non-sonographers to use UltraSightTM Real-Time Guidance for patients that require echocardiogram

By applying the power of machine learning to imaging, our aim is to streamline patient cardiac workflows with UltraSightTM Real-Time Guidance for better, more efficient, and effective care.” - Davidi Vortman, CEO of UltraSightTMTEL AVIV, ISRAEL, February 11, 2025 /EINPresswire / -- UltraSightTM , a pioneer in digital health transforming cardiac ultrasound with machine learning, today announced support from Bristol-Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).

Cardiac ultrasound is routinely utilized as an essential tool in the diagnosis and management of oHCM.

“UltraSightTM was founded with the goal of giving clinicians the ability to scan patients, wherever patients may be,” said Davidi Vortman, CEO of UltraSightTM.“By applying the power of machine learning to imaging, our aim is to streamline patient cardiac workflows with UltraSightTM Real-Time Guidance for better, more efficient, and effective care. We are thrilled to receive support from BMS on this study with the goal of evaluating how this technology could help patients in need of consistent and reliable cardiac follow-up.”

The study will be launched at Cleveland Clinic and will focus on oHCM patients with the aim to validate the quality and accuracy of the monitoring echocardiograms performed by non-sonographers using UltraSightTM's Real-Time Guidance software.

UltraSightTM's Real-Time Guidance software provides real-time assistance for healthcare providers, guiding them to acquire diagnostic-quality echocardiography images. This approach is designed to optimize and streamline cardiac monitoring and other clinical workflows, enabling non-sonographers to achieve consistent, diagnostic-quality ultrasound thus improving patient access, operational efficiency, and patient care. By putting cardiac ultrasound in the hands of any medical professional, UltraSightTM's software can help expand access to care, bringing cardiac ultrasound to more hospitals and cardiology clinics across the country.

“At Bristol Myers Squibb, we are committed to forging the path to improve cardiac care through innovative science,” said Cecilia Marta, Vice President, US Medical Cardiovascular.“This support of UltraSightTM exemplifies our commitment to transforming patients' lives through science by supporting cutting edge research.

Recruitment for the trial will begin in 2025. Please check clinicaltrials for updates. For more information about UltraSightTM visit . For more information about Bristol-Myers Squibb, visit .

About UltraSightTM
UltraSightTM is revolutionizing cardiac care by enhancing the efficiency and productivity of cardiac ultrasound. Our deep learning based Real-Time Guidance software empowers any healthcare providers to acquire diagnostic-quality echocardiography images, regardless of experience level, optimizing workflows and expanding access to cardiac ultrasound. By democratizing access to cardiac ultrasound, UltraSightTM aims to improve patient access, operational efficiency, and overall patient care. UltraSightTM's software has FDA 510(k) Clearance and is UKCA and CE Marked to assist medical professionals in performing cardiac ultrasound scans. For more news and information, visit our website or follow UltraSightTM on LinkedIn and X (Twitter).

Media Contact:

Madelyn De Los Santos
Putnam Insights LLC
+1 646-359-4361
email us here
Visit us on social media:
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MENAFN11022025003118003196ID1109192410